Minimal residual disease monitoring in multiple myeloma
- 1 March 2002
- journal article
- review article
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 15 (1) , 197-222
- https://doi.org/10.1053/beha.2002.0192
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myelomaBlood, 2001
- Molecular features responsible for the absence of immunoglobulin heavy chain protein synthesis in an IgH− subgroup of multiple myelomaBlood, 2000
- Guidelines for Clinical and Laboratory Evaluation of Patients With Monoclonal GammopathiesArchives of Pathology & Laboratory Medicine, 1999
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996
- Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patientsBritish Journal of Haematology, 1994
- Immunoglobulin gene rearrangement in multiple myeloma: Limitations of southern blot analysisHuman Pathology, 1991
- INTENSIVE TREATMENT OF MULTIPLE MYELOMA AND CRITERIA FOR COMPLETE REMISSIONThe Lancet, 1989
- INFUSION OF VINCRISTINE AND DOXORUBICIN WITH ORAL DEXAMETHASONE AS FIRST-LINE THERAPY FOR MULTIPLE MYELOMAThe Lancet, 1989
- HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMAThe Lancet, 1983